These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 35756846)

  • 21. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update.
    Hemeryck A; Belpaire FM
    Curr Drug Metab; 2002 Feb; 3(1):13-37. PubMed ID: 11876575
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics and metabolism of perazine in the rat.
    Daniel WA; Syrek M; Haduch A; Wójcikowski J
    J Pharm Pharmacol; 2001 Apr; 53(4):449-61. PubMed ID: 11341361
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Fluvoxamine in the treatment of depressive disorders in alcohol dependence: results of randomized open-label comparative study].
    Vinnikova MA; Severtsev VV; Komarov SD; Vdovin AS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(12):57-62. PubMed ID: 35041313
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical pharmacokinetics of selective serotonin reuptake inhibitors.
    van Harten J
    Clin Pharmacokinet; 1993 Mar; 24(3):203-20. PubMed ID: 8384945
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differences in interactions of SSRIs.
    Brøsen K
    Int Clin Psychopharmacol; 1998 Sep; 13 Suppl 5():S45-7. PubMed ID: 9817620
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Some aspects of genetic polymorphism in the biotransformation of antidepressants.
    Brøsen K
    Therapie; 2004; 59(1):5-12. PubMed ID: 15199661
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The pharmacogenetics of the selective serotonin reuptake inhibitors.
    Brøsen K
    Clin Investig; 1993 Dec; 71(12):1002-9. PubMed ID: 8124052
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The oxidative metabolism of metoprolol in human liver microsomes: inhibition by the selective serotonin reuptake inhibitors.
    Belpaire FM; Wijnant P; Temmerman A; Rasmussen BB; Brøsen K
    Eur J Clin Pharmacol; 1998 May; 54(3):261-4. PubMed ID: 9681670
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Marsdenia tenacissima extract inhibits gefitinib metabolism in vitro by interfering with human hepatic CYP3A4 and CYP2D6 enzymes.
    Han SY; Zhao HY; Zhou N; Zhou F; Li PP
    J Ethnopharmacol; 2014; 151(1):210-7. PubMed ID: 24157377
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update.
    Spina E; Santoro V; D'Arrigo C
    Clin Ther; 2008 Jul; 30(7):1206-27. PubMed ID: 18691982
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes.
    Crewe HK; Lennard MS; Tucker GT; Woods FR; Haddock RE
    Br J Clin Pharmacol; 1992 Sep; 34(3):262-5. PubMed ID: 1389951
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression. Are they all alike?
    Sánchez C; Meier E
    Psychopharmacology (Berl); 1997 Feb; 129(3):197-205. PubMed ID: 9084057
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Concomitant use of selective serotonin reuptake inhibitors with other cytochrome P450 2D6 or 3A4 metabolized medications: how often does it really happen?
    Gregor KJ; Way K; Young CH; James SP
    J Affect Disord; 1997 Oct; 46(1):59-67. PubMed ID: 9387087
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors?
    Rasmussen BB; Brøsen K
    Ther Drug Monit; 2000 Apr; 22(2):143-54. PubMed ID: 10774624
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of selective serotonin reuptake inhibitors: clinical relevance.
    Catterson ML; Preskorn SH
    Pharmacol Toxicol; 1996 Apr; 78(4):203-8. PubMed ID: 8861776
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of hepatic cytochrome P450s in the cytotoxicity of sertraline.
    Chen S; Wu Q; Li X; Li D; Fan M; Ren Z; Bryant M; Mei N; Ning B; Guo L
    Arch Toxicol; 2020 Jul; 94(7):2401-2411. PubMed ID: 32372212
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting.
    Grasmäder K; Verwohlt PL; Rietschel M; Dragicevic A; Müller M; Hiemke C; Freymann N; Zobel A; Maier W; Rao ML
    Eur J Clin Pharmacol; 2004 Jul; 60(5):329-36. PubMed ID: 15168101
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs.
    Richelson E
    Mayo Clin Proc; 1997 Sep; 72(9):835-47. PubMed ID: 9294531
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimizing drug selection in psychopharmacology based on 40 significant CYP2C19- and CYP2D6-biased adverse drug reactions of selective serotonin reuptake inhibitors.
    Eugene AR
    PeerJ; 2019; 7():e7860. PubMed ID: 31616600
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the effects of the selective serotonin-reuptake inhibitors fluoxetine, paroxetine, citalopram and fluvoxamine in alcohol-preferring cAA rats.
    Maurel S; De Vry J; Schreiber R
    Alcohol; 1999 Apr; 17(3):195-201. PubMed ID: 10231167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.